Home › NDC Lookup › RxCUI directory › RxCUI 310594

Gramicidin 0.025 MG/ML / neomycin 1.75 MG/ML / polymyxin B 10000 UNT/ML Ophthalmic Solutio... — RxCUI 310594

Name: Gramicidin 0.025 MG/ML / neomycin 1.75 MG/ML / polymyxin B 10000 UNT/ML Ophthalmic So… (RxCUI 310594)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic clinical drug

RxCUI 310594 Semantic clinical drug · SCD ● Current RxNorm concept 2 FDA products 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI310594

Official nameGramicidin 0.025 MG/ML / neomycin 1.75 MG/ML / polymyxin B 10000 UNT/ML Ophthalmic Solution

Concept typeSemantic clinical drug (SCD)

RxNorm statusCurrent RxNorm concept

Also known asgramicidin 0.025 MG / neomycin (as neomycin sulfate) 1.75 MG / polymyxin B (as polymyxin B sulfate) 10,000 UNT per ML Ophthalmic Solution; gramicidin 0.025 MG / neomycin sulfate 1.75 MG / polymyxin B sulfate 10,000 UNT per ML Ophthalmic Solution

FDA products mapped2

Package NDCs mapped2

Reported Medicaid activity (SDUD)1,184 prescriptions · 15 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Neomycin Topical: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

It's a first-aid antibiotic you put directly on the skin to help prevent infection in minor cuts, scrapes, and small burns. It's not meant for serious wounds or large areas of the...
Apply it directly to the affected area of skin. Follow the directions on your specific product label for how often to use it. As a general rule, don't use it for more than one week...
The main thing to watch for is a rash or any sign of an allergic reaction — like increased redness, swelling, or itching at or near the application site. If that happens, stop usin...
What should I watch out for while using it?

📖 Read our full Neomycin Topical guide →

🕸️ Concept Web — How Gramicidin 0.025 MG/ML / neomycin 1.75 MG/ML / p... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept Gramicidin 0.025 MG/ML / neomycin 1.75 MG/ML / polymyxin B 10000 UNT/ML Ophthalmic Solution RxCUI 310594 Semantic clinical drug · SCD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 4

The active substance itself — no strength, form, or brand attached yet.
- Gramicidin 5011 IN
- Neomycin 7299 IN
- Polymyxin B 8536 IN
- Gramicidin / neomycin / polymyxin B 692794 MIN
Dose forms 4

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Gramicidin / neomycin / polymyxin B Ophthalmic Solution 374686 SCDF
- Gramicidin / neomycin / polymyxin B Ophthalmic Product 1156888 SCDG
- Ophthalmic Solution 7670 DF
- Ophthalmic Product 1151135 DFG
Clinical & branded drugs 3

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- Gramicidin 0.025 MG/ML 335918 SCDC
- Neomycin 1.75 MG/ML 336873 SCDC
- Polymyxin B 10000 UNT/ML 316526 SCDC

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Gramicidin 0.025 MG/ML SCDC · 335918
Neomycin 1.75 MG/ML SCDC · 336873
Polymyxin B 10000 UNT/ML SCDC · 316526
Gramicidin / neomycin / polymyxin B Ophthalmic Solution SCDF · 374686
Gramicidin / neomycin / polymyxin B Ophthalmic Product SCDG · 1156888

📦 FDA Products & Package NDCs

2 products · 2 package NDCs

2 package NDCs map to RxCUI 310594 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
24208-0790-62	1 BOTTLE, DROPPER in 1 CARTON (24208-790-62) / 10 mL in 1 B...	NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN	Bausch & Lomb Incorporated	1996-01-31
50090-0247-00	1 BOTTLE, DROPPER in 1 CARTON (50090-0247-0) / 10 mL in 1 B...	NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN	A-S Medication Solutions	2016-06-29

Observed labelers: A-S Medication Solutions (1) · Bausch & Lomb Incorporated (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.

Per ml · median

$4.6398

Range $4.6398–$4.6398 · middle 50% $4.6398–$4.6398 · 1 NDCs

Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.